Trial Profile

A Phase 1 Dose Escalation With Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMV564 Alone and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 06 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Vixtimotamab (Primary)
Indications Appendiceal cancer; Endometrial cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Penile cancer; Rectal cancer; Skin cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Amphivena Therapeutics

11 Oct 2021 Planned End Date changed from 15 Sep 2022 to 31 Dec 2021.
11 Oct 2021 Planned primary completion date changed from 15 Sep 2021 to 15 Dec 2021.
11 Oct 2021 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com